Benefit from perioperative enfortumab vedotin–pembrolizumab in cisplatin-eligible MIBC

Nature Reviews Clinical Oncology, Published online: 04 August 2026; doi:10.1038/s41571-026-01195-2Benefit from perioperative enfortumab vedotin–pembrolizumab in cisplatin-eligible MIBC

dlvr.it

More options, more questions in the management of early relapsed and/or refractory multiple myeloma

Nature Reviews Clinical Oncology, Published online: 31 July 2026; doi:10.1038/s41571-026-01191-6In MonumenTAL-3, the G-protein-coupled receptor class C group 5 memberD-directed bispecific T cell engager talquetamab combined with either daratumumab or daratumumab–pomalidomide conferred significantly longer progression-free survival than daratumumab–pomalidomide–dexamethasone in patients with relapsed and/or refractory multiple myeloma (≥1 prior line of therapy). These results herald a new therapeutic option for such patients but also raise questions regarding how talquetamab-based regimens should be integrated with B cell maturation antigen-directed T cell-redirecting therapies.

dlvr.it

Clinical toxicity of ADCs and ICI–ADC combinations: mechanisms, patterns and management

Nature Reviews Clinical Oncology, Published online: 30 July 2026; doi:10.1038/s41571-026-01188-1With the expanded use of antibody–drug conjugates (ADCs) and immune checkpoint inhibitors (ICIs) in combination, clinicians increasingly face overlapping toxicity profiles with uncertain attribution. The authors of this Review propose a framework that links three interacting layers: immune activation, payload cytotoxicity and payload-independent effects, and provide practical algorithms for evaluation, initial management and treatment resumption in patients receiving ADC monotherapy or ICI–ADC combinations.

dlvr.it

De-escalation trials in multiple myeloma: past, present and future

Nature Reviews Clinical Oncology, Published online: 29 July 2026; doi:10.1038/s41571-026-01186-3Current treatment approaches for patients with multiple myeloma are characterized by a ‘more is better’ philosophy aiming for deep and long-term clinical responses. The authors of this Review challenge this paradigm, presenting several de-escalation strategies that do not compromise long-term efficacy and proposing a framework for the design of trials testing further de-escalation approaches.

dlvr.it

Electronic cigarettes, smoking and lung cancer risk: some evidence about the continuum of harm

Nature Reviews Clinical Oncology, Published online: 28 July 2026; doi:10.1038/s41571-026-01192-5Since the introduction of vaping with electronic cigarettes in the late 2000s, controversy has continued to exist regarding the risks and benefits. Many studies indicate that electronic cigarettes are an effective smoking-cessation tool. Now, a large database analysis by Kim et al. provides a glimpse of the risks of lung cancer for smokers who quit with versus without vaping.

dlvr.it

Towards liquid biopsy-based analysis of antitumour immunity

Nature Reviews Clinical Oncology, Published online: 24 July 2026; doi:10.1038/s41571-026-01181-8Advances in multimodal analyses of diverse cell types and cellular products present in the blood have presented opportunities to non-invasively and repeatedly assess systemic immune dynamics, predict and monitor responses to immunotherapies, and detect emerging resistance in patients with cancer. In this Review, the authors discuss various insights on systemic antitumour immune responses that can be gleaned through such liquid biopsy-based analysis of circulating tumour-derived biomarkers and/or immune cells and their implications for immunotherapy.

dlvr.it

Does OptiTROP-Lung05 open a new frontier for first-line ADC–ICI combinations in NSCLC?

Nature Reviews Clinical Oncology, Published online: 20 July 2026; doi:10.1038/s41571-026-01183-6Interim data from the phase III OptiTROP-Lung05 trial demonstrate that adding the TROP2-targeted antibody–drug conjugate sacituzumab tirumotecan to pembrolizumab improves progression-free survival in patients with PD-L1-positive advanced-stage non-small-cell lung cancer. Herein, I present several questions that need to be addressed before this combination can be considered a new standard of care, such as effect on overall survival, long-term safety, global generalizability and biomarker refinement.

dlvr.it

Second-line 177Lu-edotreotide shows promise in GEP NETs

Nature Reviews Clinical Oncology, Published online: 16 July 2026; doi:10.1038/s41571-026-01187-2Second-line 177Lu-edotreotide shows promise in GEP NETs

dlvr.it

Crossover does not confound, it informs: 177lutetium-PSMA-617 as an example

Nature Reviews Clinical Oncology, Published online: 16 July 2026; doi:10.1038/s41571-026-01182-7Crossover in trials should not be viewed as confounding, but as informative. Crossover reveals whether deferring therapy produces outcomes comparable to those from earlier use. Statistical crossover-adjustment methods carry unaccounted biases and limited clinical utility. Crossover should instead guide treatment-sequencing decisions, weighing toxicity and cost against any overall survival benefit from earlier intervention.

dlvr.it

The future of ciltacabtagene autoleucel in multiple myeloma has just begun

Nature Reviews Clinical Oncology, Published online: 14 July 2026; doi:10.1038/s41571-026-01184-5The future of ciltacabtagene autoleucel in multiple myeloma has just begun

dlvr.it

Ciltacabtagene autoleucel heralds the arrival of fixed-duration therapies in myeloma

Nature Reviews Clinical Oncology, Published online: 14 July 2026; doi:10.1038/s41571-026-01185-4Ciltacabtagene autoleucel heralds the arrival of fixed-duration therapies in myeloma

dlvr.it

CRISPR in clinical oncology: translational advances from molecular diagnostics to therapeutics

Nature Reviews Clinical Oncology, Published online: 09 July 2026; doi:10.1038/s41571-026-01179-2CRISPR–Cas technologies provide a modular, programmable platform for sequence-specific targeting of DNA or RNA and have advanced from experimental molecular biology tools to clinical translation. This Review describes current and emerging applications of CRISPR–Cas platforms in oncology, including their use in discovery research, diagnostics and therapeutics.

dlvr.it

Improving neoadjuvant and perioperative therapy in non-small-cell lung cancer

Nature Reviews Clinical Oncology, Published online: 30 June 2026; doi:10.1038/s41571-026-01174-7Perioperative chemoimmunotherapy, comprising platinum-doublet chemotherapy plus an anti-PD-(L)1 antibody, has become the standard-of-care approach for patients with resectable non-small-cell lung cancer without an actionable driver alteration. However, the development of this approach has thus far been largely empirical, with limited capacity for adaptation of treatment strategies to better meet the needs of individual patients. In this Review, the authors discuss the potential for improvements in the current approach to perioperative therapy, including de-escalation for those with a pathological complete response, the capacity of various baseline and/or dynamic biomarkers to optimize outcomes, and the potential for escalation in patients with early evidence of a lack of responsiveness in the perioperative setting.

dlvr.it

Patient value over patent value: the mandate for open-source oncology

Nature Reviews Clinical Oncology, Published online: 26 June 2026; doi:10.1038/s41571-026-01180-9Modern oncology has built highly efficient pathways for patent-protected innovation, but no equivalent machinery for evaluating and developing promising off-patent therapeutics. Herein, we frame ‘open-source oncology’ as a parallel public-interest infrastructure to test, authorize and implement credible generic agents. Designed to translate ownerless evidence into standard-of-care treatments, this framework applies the same scientific seriousness devoted to proprietary drugs, decoupling clinical value from commercial ownership.

dlvr.it

Cancer burden and control in China: landscape, trends and challenges

Nature Reviews Clinical Oncology, Published online: 19 June 2026; doi:10.1038/s41571-026-01165-8Over the past decades, cancer epidemiology trends have substantially shifted in China, with a rapid increase in incidence of cancers that are most common in high-income countries and a substantial decline in incidence of cancers historically prevalent in China. The authors of this Review provide an overview of cancer epidemiology in China, a major contributor to global cancer burden, and discuss national cancer control policies and targets.

dlvr.it

New standards and new constraints redefine treatment sequencing in platinum-resistant ovarian cancer

Nature Reviews Clinical Oncology, Published online: 17 June 2026; doi:10.1038/s41571-026-01168-5The therapeutic landscape of platinum-resistant ovarian cancer is rapidly evolving, with recent phase III trials demonstrating, for the first time, meaningful overall survival improvements beyond bevacizumab-based therapy. Herein we discuss how trials such as MIRASOL and, more recently, ENGOT-ov65/KEYNOTE-B96 and GOG30173/ENGOT-ov72/ROSELLA have established new standards of care through distinct biologically driven therapies and outline the new challenges that these approaches expose.

dlvr.it

Antibody–drug conjugates in gynaecological cancers: opportunities and challenges

Nature Reviews Clinical Oncology, Published online: 17 June 2026; doi:10.1038/s41571-026-01164-9Three antibody–drug conjugates (ADCs) are currently approved for previously treated gynaecological cancers: mirvetuximab soravtansine for folate receptor-α-positive ovarian cancer, trastuzumab deruxtecan for solid tumours expressing HER2 and tisotumab vedotin for cervical cancer (independent of tissue factor expression). The authors of this Review discuss current priorities in the clinical development of ADCs for gynaecological cancers, such as identifying novel targets, understanding mechanisms of resistance and sequencing strategies, and managing toxicities, highlighting key advances and future opportunities.

dlvr.it

Teclistamab monotherapy improves survival in RRMM

Nature Reviews Clinical Oncology, Published online: 15 June 2026; doi:10.1038/s41571-026-01178-3Teclistamab monotherapy improves survival in RRMM

dlvr.it

Potential new standard of care for resectable gastro-oesophageal adenocarcinoma in Asia

Nature Reviews Clinical Oncology, Published online: 12 June 2026; doi:10.1038/s41571-026-01177-4Potential new standard of care for resectable gastro-oesophageal adenocarcinoma in Asia

dlvr.it

Daraxonrasib effective in metastatic pancreatic ductal adenocarcinoma

Nature Reviews Clinical Oncology, Published online: 12 June 2026; doi:10.1038/s41571-026-01176-5Daraxonrasib effective in metastatic pancreatic ductal adenocarcinoma

dlvr.it

Adjuvant selpercatinib shows benefit in patients with NSCLC

Nature Reviews Clinical Oncology, Published online: 11 June 2026; doi:10.1038/s41571-026-01172-9Adjuvant selpercatinib shows benefit in patients with NSCLC

dlvr.it

Ivonescimab improves overall survival

Nature Reviews Clinical Oncology, Published online: 11 June 2026; doi:10.1038/s41571-026-01175-6Ivonescimab improves overall survival

dlvr.it

From ASCO 2026

Nature Reviews Clinical Oncology, Published online: 11 June 2026; doi:10.1038/s41571-026-01173-8From ASCO 2026

dlvr.it

Trial design and end points in hepatocellular carcinoma: an EASL–AASLD–ILCA consensus statement

Nature Reviews Clinical Oncology, Published online: 10 June 2026; doi:10.1038/s41571-026-01160-zDespite considerable improvements in the outcomes in patients with hepatocellular carcinoma (HCC), many outstanding research questions remain unanswered. Furthermore, significant findings from successful phase III trials have not always been translated into guideline-recommended therapies, implying a need for improved standardization of trial end points. In this Consensus Statement, representatives of four major societies (the European Association for the Study of the Liver (EASL), the American Association for the Study of Liver Diseases (AASLD), the International Liver Cancer Association (ILCA) and the American Society of Clinical Oncology (ASCO)) convened to provide guidance on end point selection for clinical trials conducted in various settings including surveillance, and early-stage, intermediate-stage and advanced-stage HCC.

dlvr.it

The future is not always uniform: rethinking radiotherapy through spatial fractionation

Nature Reviews Clinical Oncology, Published online: 10 June 2026; doi:10.1038/s41571-026-01161-yTraditional radiotherapy approaches involve the delivery of a uniform radiation dose to the entire tumour. Despite considerable effectiveness, this approach comes with the limitations of a lack of activity against larger tumour volumes as well as off-target irradiation of surrounding non-malignant tissues. Spatially fractionated radiotherapy, involving deliberate non-uniform irradiation, has the potential to address these challenges, with early data suggesting safety and activity in patients with advanced-stage cancers. In this Review, the authors describe the emerging role of spatially fractionated radiotherapy in the management of patients with cancer.

dlvr.it

RECITE this mantra in chemotherapy-induced thrombocytopenia: treat patients, not platelets

Nature Reviews Clinical Oncology, Published online: 09 June 2026; doi:10.1038/s41571-026-01170-xRecent data from the RECITE trial indicating that the thrombopoietin receptor agonist romiplostim ameliorates chemotherapy-induced thrombocytopenia offer hope for the first drug treatment for this condition. However, the ultimate goal is not to improve platelet counts but patient outcomes, and RECITE does not offer evidence of survival or quality-of-life benefits that truly matter to patients.

dlvr.it

Does ciltacabtagene autoleucel have a future in multiple myeloma?

Nature Reviews Clinical Oncology, Published online: 08 June 2026; doi:10.1038/s41571-026-01159-6Ciltacabtagene autoleucel (cilta-cel) has transformed the outcomes of patients with relapsed or refractory multiple myeloma, yet its toxicity profile — spanning acute and delayed-onset neurotoxicity, secondary malignancies, immune effector-cell colitis, infections and prolonged cytopenias — has emerged slowly. As safer alternatives become available, the risk–benefit calculus for cilta-cel demands urgent reassessment, particularly in earlier lines of therapy.

dlvr.it

Realizing the benefits of tumour-agnostic access requires a national health learning system

Nature Reviews Clinical Oncology, Published online: 08 June 2026; doi:10.1038/s41571-026-01167-6The Australian Pharmaceutical Benefits Advisory Committee’s decision to allow tumour-agnostic reimbursement of nivolumab and ipilimumab is a bold experiment that involves a considerable level of risk-sharing between government, industry, clinicians and patients. The central policy challenge now is whether Australia has sufficient infrastructure and initiative to convert this access into timely and decision-relevant evidence. Reimbursement that accelerates access despite uncertainty carries an obligation to learn.

dlvr.it

Ibrutinib improves overall survival in patients with mantle cell lymphoma

Nature Reviews Clinical Oncology, Published online: 03 June 2026; doi:10.1038/s41571-026-01166-7Ibrutinib improves overall survival in patients with mantle cell lymphoma

dlvr.it

First-line zanidatamab–chemotherapy with or without tislelizumab improves survival in advanced-stage HER2+ GEA

Nature Reviews Clinical Oncology, Published online: 02 June 2026; doi:10.1038/s41571-026-01169-4First-line zanidatamab–chemotherapy with or without tislelizumab improves survival in advanced-stage HER2+ GEA

dlvr.it